Kornimate/medical-research-clean huggingface dataset:
retrospective study on myoelectric elbow-wrist-hand orthosis user outcomes

Conditions: Stroke; Brachial Plexus Injury; Spinal Cord Injuries; Neurological Disease

Summary: the objective of this study is to retrospectively evaluate the outcomes and clinical benefits provided by this brace to adult patients with upper limb impairment or paralysis due to brachial plexus, stroke (cva), spinal cord injury, or other neurological disease or injury.

the objective of this study is to retrospectively evaluate the outcomes and clinical benefits provided by this brace to adult patients with upper limb impairment or paralysis due to brachial plexus, stroke (cva), spinal cord injury, or other neurological disease or injury. the primary result in this study is a comparison of the disabilities of the arm, shoulder and hand questionnaire results that were completed before and at least six months after receiving the myopro. a retrospective record review will be done to collect data regarding myopro user outcomes for individuals that received a myopro starting january 2021 and after. additional data types such as demographics and clinical outcomes will be gathered. participants may complete at least one follow-up session to record responses to additional inquiries from the research team.

Eligibility criteria:
inclusion criteria: * adults, 65 years and older at the time of myopro delivery * completed the dash questionnaire at evaluation before receiving the myopro * completed the dash questionnaire at least six months after receiving the myopro * has intact cognition * able to clearly and verbally communicate in the english language exclusion criteria: * life-changing event(s) or change(s) in medical status that affected ability to use the myopro * did not complete the dash after receiving the myopro * other conditions (e.g., cognitive issues) or circumstances that would preclude safe and/or effective participation

Keywords: myopro
dose efficacy in adhesive capsulitis

Conditions: Adhesive Capsulitis of the Shoulder

Summary: the purpose of this study is to find out if the treatment of adhesive capsulitis with 40 mg of methylprednisolone in combination with a hydrodilatation is comparable to 80 mg of methylprednisolone for pain reduction, improving shoulder mobility, and reducing side effects. researchers will enroll 40 people in this study which is taking place solely at the toronto rehabilitation institute, university avenue. this study should take approximately 12 months to complete and the results should be known in about 15 to 18 months. during this study, patients will receive an ultrasound guided shoulder hydrodilatation combined with corticosteroid after "randomized" into one of the groups (40 mg vs 80 mg). this is a double blind study as both patients and physicians would not know the group patient was randomized to. pain scores, range of motion and few other questionnaires wold be completed to track the response to the interventions at baseline prior to injection, four weeks after the procedure and 3 months after the procedure.


Eligibility criteria:
inclusion criteria: * \>18 years of age * diagnostic of adhesive capsulitis of the shoulder exclusion criteria: * injection received in the affected shoulder \< 3 months ago (any kind) * history of previous surgery in the affected shoulder * glenohumeral osteoarthritis more than mild on the xray * pregnancy * blood thinner (other than aspirin 80 mg) or bleeding disorder * active infection (requiring antibiotic) * allergy to steroid or lidocaine * cognitive impairment * active litigation * inflammatory connective tissue disorder

Keywords: frozen shoulder hydrodilatation
safety, tolerability and efficacy of transcon hgh weekly versus daily hgh in chinese pediatric growth hormone deficiency

Conditions: Growth Hormone Deficiency; Endocrine System Diseases; Hormones; Pituitary Diseases; Pituitary Disease, Anterior

Summary: this study is conducted in china only. the purpose is to demonstrate the efficacy and safety of once weekly dosing of transcon hgh, a long-acting growth hormone product, compare to once-daily dosing of human growth hormone (hgh) after 52 weeks of treatment in prepubertal children with growth hormone deficiency (ghd).

not provided

Eligibility criteria:
inclusion criteria: * prepubertal children with ghd in tanner stage 1, aged of 3 years and below 17 years; * impaired ht defined as at least 2.0 standard deviations (sd) below the mean height for chronological age and sex (ht sds≤-2.0) according to the chinese 2005 standard； * diagnosis of ghd confirmed by 2 different gh stimulation tests, defined as a peak gh level of ≤10 ng/ml, determined with a validated assay. bone age (ba) at least 6 months less than the chronological age； * baseline igf-1 level of at least 1.0 sd below the mean igf-1 level standardized for age and sex (igf-1 sds ≤-1.0)； * written, signed informed consent of the parent(s) or legal guardian(s) of the subject and written assent of the subject (if the subject is 8 years old or above). exclusion criteria: * children with a body weight below 12 kg； * prior exposure to recombinant hgh or igf-1 therapy； * children with past or present intracranial tumor growth as confirmed by a sellar mri scan (with contrast dye recommended) at screening * children born sga (birth weight ≤10th percentile for gestational age according to the chinese reference)； * children with psychosocial dwarfism； * children with idiopathic short stature； * other causes of short stature such as coeliac disease, hypothyroidism, or rickets； * history or presence of malignant disease; any evidence of present tumor growth; * subjects with diabetes mellitus； * closed epiphyses； * major medical conditions and/or presence of contraindication to hgh treatment； * participation in any other trial of an investigational agent within 3 months prior to screening.

Keywords: growth hormone deficiency transcon hgh human growth hormone hgh
moxibustion in the treatment of hemorrhagic cystitis after allo-hsct

Conditions: Moxibustion; Hematopoietic Stem Cell Transplantation; Hemorrhagic Cystitis; Treatment

Summary: this study was a prospective, multicenter, single-arm clinical study planned to enroll 60 patients who developed hemorrhagic cystitis after sexually allogeneic hematopoietic stem cell transplantation patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation were given symptomatic supportive treatment combined with moxibustion covering shenque, zhongguo, guanyuan, and qihai for 30 minutes every day for 14 days and urine routine was collected every day for 14 days to assess the severity of hemorrhagic cystitis and pain scores to evaluate the effectiveness of moxibustion in treating hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.


Eligibility criteria:
inclusion criteria: 1. patients were fully aware of the study, participated voluntarily, and signed the informed consent form; 2. age: 18-55 years old; 3. patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation; exclusion criteria: 1. refusal to participate in this clinical study; 2. broken or sensitized skin corresponding to the moxibustion site; 3. allogeneic hematopoietic stem cell transplantationpatients pretreated with the reduced-intensity conditioning.
postoperative pain after activation of irrigant

Conditions: Pain

Summary: the purpose of this research is to analyze the levels of pain after cleaning and shaping in individuals who are receiving root canal therapy using the ivac irrigation approach, and those who are treated with ultrasonic irrigation techniques, negative pressure irrigation technique and traditional irrigation techniques. picots question: does the new dent's ivac irrigation protocol has an effect on reduction of postoperative pain by enlisting at least 84 suitable individuals who are undergoing the identical endodontic procedure. pain will be measures by assessing pain levels through a standardized numerical rate scale (nrs) at certain time intervals after root canal treatment, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours.


Eligibility criteria:
inclusion criteria: males and females age :20-50 mandibular mature first molars with symptomatic acute pulpitis medically free patients exclusion criteria: pulp necrosis or apical periodontitis periodontal disease vertical root fracture radiographic apical radiolucency -
the effect of humidification on mucus rheology

Conditions: Chronic Obstructive Pulmonary Disease(COPD)

Summary: in this study the investigators will collect mucus from mechanical ventilated patients and patients with copd to study the effect of temperature and humidity, on the biophysical properties of the airway mucus. it is hypothesised that changes in inspired gas temperature and humidity (over time) may affect the biophysical properties of the airway mucus and reduce the airway's ability to clear mucus, resulting in deleterious clinical affects.

expectorated sputum samples are collected and used to measure the biophysical properties of mucus secretions. the samples are later exposed to different temperatures and humidity levels during bench experiments.

Eligibility criteria:
mechanically ventilated patients inclusion criteria: any subject mechanically ventilated and producing sputum. exclusion * none copd group inclusion criteria: * 40 to 90 years of age suffering from copd * history of mucus production exclusion criteria: * none
multi-component prehabilitation for major elective surgery

Conditions: Frailty

Summary: the purpose of this pilot study is to assess the feasibility of delivering a multicomponent prehabilitation and measuring patient-centered outcomes in older adults undergoing major surgery.

we will assess the feasibility of delivering a multicomponent prehabilitation, which consists of exercise (supervised by physical therapist), nutritional intervention (nutritional supplement and group education), meditation (group class), and cognitive behavioral intervention over 3-4 weeks before major elective abdominal, gynecological oncologic, urologic surgery, and cardiovascular procedures. we will also measure patient-centered outcomes (patient-reported outcomes measurement information system) at 30 and 90 days after surgery. the target enrollment is 30 patients.

Eligibility criteria:
inclusion criteria: * patient is scheduled to have a gastrointestinal, gynecological oncologic, urologic, and cardiovascular procedure * age 70 years+ * age 65 years+ and high risk per surgeon's clinical judgment * patient provides an informed e-consent or remote consent exclusion criteria: * surgery is scheduled less than 21 days * patient is considered an inappropriate candidate per the surgeon's assessment * non-english speaking * patient has a major cognitive impairment confirmed by telephone montreal cognitive assessment (moca) \<18 or brief capacity assessment questionnaire * patients with chronic kidney disease stage 3 or higher will be excluded from receiving protein supplement of the prehabilitation program

Keywords: prehabilitation
efficacy and safety of repaglinide, glurenorm® and glucobay® in chinese subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in asia. the aim of this trial is to compare the efficacy and safety of repaglinide and glurenorm® and glucobay® given as the mono-therapy in chinese subjects being treatment-naive type 2 diabetics.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * no previous treatment for diabetes * hba1c: 7.0-12.0% exclusion criteria: * type 1 diabetes * uncontrolled treated/untreated hypertension * any condition that the investigator and/or sponsor feels would interfere with trial participation or evaluation of results * pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures (adequate contraceptive measures are: sterilisation, intra-uterine device (iud), oral contraceptives or barrier methods)
suitable method for routine diagnostics of eer in children with otitis media with effusion

Conditions: Otitis Media With Effusion

Summary: the aim of the study was detection of pepsin in effusion in children with ome using peptest as new quick and cheap method of detection and comparison results with results of other studies in which pepsin was detected by more demanding methods. such a type of study hasn't been done so far.

children at the age between 1 to 7 years diagnosed with bilateral or unilateral ome who underwent adenoidectomy and myringotomy with insertion of ventilation tube were included in the prospective study. ome was defined as effusion in the middle ear behind intact eardrum longer than 3 months. diagnosis was made on the basis of otomicroscopic findings, pneumatic otoscopy, type b tympanometry and audiometry (in older cooperative children). children with no fluid in middle ear during myringotomy were revised as having tympanosclerosis and were excluded from the study. children with craniofacial abnormities (down syndrome, treacher collins syndrome, clefts etc.) were excluded from the study, as well. demographic data and symptoms of eer disease were provided by parents, who were particularly inquired regarding the hoarseness, recurrent lower respiratory infection (bronchitis, pneumonia) and bronchial asthma of their child. myringotomy using microscope was done in anterior inferior part of the tympanic membrane. type of middle ear effusion (fluid, mucous) was registered. middle ear fluid was collected by special suction device with collecting bottle and ventilation tube was inserted in the tympanic membrane. in case of bilateral ome, effusion was collected and analysed separately. specimen was first standardized. an amount of 0.1 ml of 10 % citric acid was added, specimen was centrifuged for 10 minutes and subsequently original migration reagent was added. afterwards, specimen was examined using peptest, which contains monoclonal antibodies targeted against pepsin. result of the peptest was stated as positive (2 lines), negative (1 line) and invalid (no line). peptest detection limit is 16ng/ml of pepsin. statistical analysis was done using ms excel.

Eligibility criteria:
inclusion criteria: * signing of the informed consent * children at the age between 1 to 7 years diagnosed with bilateral or unilateral ome exclusion criteria: * children with craniofacial abnormities (down syndrome, treacher collins syndrome, clefts etc.)

Keywords: otitis media with effusion laryngopharyngeal reflux
impact of body mass index and lipid metabolism on anti-pd-1 immunotherapy outcomes in colorectal cancer

Conditions: Colo-rectal Cancer

Summary: this observational study aims to evaluate the impact of body mass index (bmi) and dyslipidemia on the effectiveness of anti-pd-1 immunotherapy in patients with colorectal cancer (crc). a total of 142 patients treated with immune checkpoint inhibitors at sun yat-sen university cancer center were retrospectively analyzed. the study assessed progression-free survival (pfs) based on bmi and lipid profiles. lipidomic profiling was also performed to explore potential metabolic mechanisms. the aim of this study was to identify simple, clinically applicable biomarkers to guide treatment decisions for crc patients receiving immunotherapy.

this retrospective observational study investigates the prognostic value of body mass index (bmi) and dyslipidemia in colorectal cancer (crc) patients treated with anti-pd-1 immune checkpoint inhibitors (icis). a total of 142 patients were included, all of whom received at least two cycles of pd-1 inhibitors, including camrelizumab, nivolumab, pembrolizumab, sintilimab, tislelizumab, or toripalimab, at sun yat-sen university cancer center between january 1, 2019, and december 31, 2022. the primary objective of the study was to evaluate progression-free survival (pfs) stratified by bmi and lipid profile status. patients were grouped by bmi into normal (\<24 kg/m²) and overweight (≥24 kg/m²) categories, based on who standards for the chinese population. dyslipidemia was defined according to standard lipid thresholds. kaplan-meier and cox proportional hazard models were used for survival analysis. additionally, a subset of 12 patients underwent pre-treatment serum lipidomic profiling using ultra-performance liquid chromatography-tandem mass spectrometry (uplc-ms/ms) to explore potential metabolic mechanisms contributing to differential responses.

Eligibility criteria:
inclusion criteria: age ≥ 18 years at time of diagnosis histologically confirmed colorectal adenocarcinoma received at least two doses of anti-pd-1 immune checkpoint inhibitor therapy (e.g., camrelizumab, nivolumab, pembrolizumab, sintilimab, tislelizumab, or toripalimab) availability of baseline body mass index (bmi) and lipid profile within 30 days prior to ici initiation adequate clinical records for retrospective data collection signed informed consent for data usage (if applicable to retrospective cohort) exclusion criteria: participation in another interventional clinical trial during the study period incomplete pd-1 treatment (\< 2 cycles) severe immune-related adverse events leading to early discontinuation of immunotherapy missing or incomplete bmi or lipid profile data loss to follow-up prior to outcome assessment
questionnaire and laboratory data on vitiligo vulgaris

Conditions: Vitiligo Vulgaris

Summary: vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). while genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. the triggers for disease onset have not yet been identified. the intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.

patients who participate in this study will be asked to complete a survey and have blood/ laboratory testing performed that relates or may relate to the diagnosis of vitiligo.

Eligibility criteria:
inclusion criteria: * diagnosis of vitiligo vulgaris * ability to sign consent exclusion criteria: * pregnant * inability to sign consent * inability to complete questionnaire

Keywords: vitiligo vulgaris
safety and efficacy of drug combinations against schistosomiasis

Conditions: Parasitic Diseases

Summary: this randomised, controlled, double-blinded clinical study investigates the safety and efficacy of mbd in combination with pzq in the treatment of sch and sth in children aged 1-15 years of age.


Eligibility criteria:
inclusion criteria: * those with an age of 1-15 years of age * are infected with schistosomiasis and soil-transmitted helminthiasis * whose parent consent and who are willing to participate exclusion criteria: * those with acute and chronic diseases other than schistosomiasis and soil-transmitted helminthiasis * those with a history of any serious adverse drug reactions
observation on the treg in the uveitis patients

Conditions: Uveitis

Summary: aim: to study the expression of cd4+cd25+ high regulatory t cells in peripheral blood of patients with uveitis and to explore its role in the development of uveitis.

uveitis describes inflammation that exists in the uveal tract, but the disease course has such a variety of manifestations. uveitis (intraocular inflammatory diseases) includes sight-threatening diseases such as behcet disease, birdshot retinochoroidopathy, vogt-koyanagi-harada, sympathetic ophthalmia and ocular sarcoidosis, and may be of infectious or autoimmune etiology. cd4+ cd25+ tr cells play a key role in the maintenance of peripheral self-tolerance by inhibiting the activation and proliferation of unreactive t cells. in addition to a direct suppressor effect on cd4+cd25+ tr cells. cd4+cd25+ tr cells may regulate the immune response through dendritic cell. like cytotoxic t-lymphocytes and natural killer cells,activated human cd4+cd25+ tr cells display perforin-dependent cytoxicity against autologous target cell, including activated cd4+ and cd8+ t cells. experimental autoimmune uveoretinitis (eau) is a model of uveitis. regulatory t cells in the uveitis are currently thought to be the etiologic agent of uveitis because ifn-γ,il-2(interleukin-2),tnf(tumor necrosis factor alpha) levels are elevated in the retina during uveitis following stimulation with il-2 expression was upregulated in pbmc(peripheral blood mononuclear cell) of healthy subjects and patients with scleritis or uveitis. by elisa, we confirmed that il-2 induced the secretion of the protein in human pbmc and in mouse cd4+t cells. experiment found, by an intracellular cytokine analysis assay, that the ifn-γ,il-2,tnf expressing cells were predominantly cd4+t cells with a memory phenotype. consistent with our rna data, the percentage of cd4+t cells was higher in scleritis patients than in healthy subjects. we analyzed peripheral blood of thirty uveitis patients enrolled in department of ophthalmology, xijing hospital clinical trials. the demographics of the patients, including age, sex, diagnosis and medications at time of sample collection . biospecimen description: experimental: a drug: prednisone profess to convinced 1-1.5mg/kg.d experimental: b drug: methotrexate profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced 0.5-1mg/kg.d methods cd4+cd25+ tr cells, ctla-4 and an intracellular cytokine analysis assay that the ifn-γ,il-2,tnf expressing cells were measured in 30 uveitis patients before and after 1 month,3 months of prednisone and methotrexate. cytokine assays. for intracellular cytokine detect, cd4+t cells were cultured as indicated above and restimulated for 5h with 1mg/ml phorbol 12-myristate 13-acetate (pma) and ionomycin (1mg/ml) in the presence of golgistop, we added antibodies (ifn-γ,il-2,tnf). we performed cytokine staining using bd biosciences and analyzed samples by flow cytometry.

Eligibility criteria:
inclusion criteria: * between 18 to 60 years * the first episode exclusion criteria: * had other intracranial pathologies (e.g.tumor,infection)

Keywords: cd4/cd25 tr cell,tnf,ifn-γ,il-2
safety & efficacy study of oral panobinostat (lbh589) with chemotherapy in patients < 65 years old with acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia (AML)

Summary: this study will be conducted to assess the maximum tolerated dose (mtd) of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine) in newly diagnosed patients with a cytopathologically confirmed diagnosis of high-risk aml, and to investigate the safety of the combination in this regimen.


Eligibility criteria:
inclusion criteria: * newly diagnosed adult patients = 65 years old with a cytopathologically confirmed diagnosis of high-risk aml * = 20% bone marrow blasts via bone marrow aspiration or biopsy * the patient has not yet been treated for aml * 1º or 2º aml patients with high-risk category features * ecog ps = 2 * renal function and liver function limits. exclusion criteria: * patient with a 'favorable' or 'better-risk' cytogenetic profile = t(15;17); t(8;21); or inv(16) or t(16;16) * patient has clinical symptoms suggestive of cns leukemia and/or csf findings for cns leukemia * prior treatment with deacetylase inhibitors (daci) including, panobinostat * impaired cardiac function * female patient who is pregnant or breast feeding * male patient who is not willing to use a barrier method of contraception other protocol-defined inclusion/exclusion criteria may apply

Keywords: aml bone marrow abnormal blast cells of myeloid acute leukemia cytogenetic abnormalities hdaci